Literature DB >> 11266402

Schizophrenia in late life: findings challenge traditional concepts.

B W Palmer1, F S McClure, D V Jeste.   

Abstract

Two notions about schizophrenia have persisted: (1) it is characterized by onset in adolescence or early adulthood, and (2) it has a progressively deteriorating course. Recent studies focusing on early-adulthood- and middle-age-onset schizophrenia challenge these views. Patients with early-onset schizophrenia and middle-age-onset schizophrenia (MAOS) are similar in terms of family history of schizophrenia, presence of minor physical anomalies, early childhood maladjustment, severity of positive symptoms, presence of gross structural abnormalities on cerebral magnetic resonance imaging, overall pattern of neuropsychologic deficits, and qualitative response to neuroleptic medications. Differences include a higher proportion of women among MAOS patients, and the tendency for MAOS patients to have less severe negative symptoms, better neuropsychologic performance (particularly in learning and abstraction/cognitive flexibility), and possibly larger thalamic volume and to respond to lower doses of neuroleptic medications. While onset of schizophrenia-like symptoms in very late life may reflect an acquired condition that is not "true schizophrenia," and that may be labeled "very-late-onset schizophrenia-like psychosis," findings suggest that true schizophrenia can arise after early adulthood. Middle-age-onset schizophrenia is predominantly neurodevelopmental, but it is also a distinct neurobiological subtype of schizophrenia. Our studies also demonstrate that neuropsychologic functioning remains stable in chronic schizophrenia outpatients, even when observed over several years and in the presence of significant fluctuations in the severity of clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11266402     DOI: 10.1080/10673220127883

Source DB:  PubMed          Journal:  Harv Rev Psychiatry        ISSN: 1067-3229            Impact factor:   3.732


  9 in total

Review 1.  Antipsychotic treatment for late-life schizophrenia.

Authors:  Jeremy A Sable; Dilip V Jeste
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

2.  Perspectives on schizophrenia over the lifespan: a qualitative study.

Authors:  Sally Shepherd; Colin A Depp; Gloria Harris; Maureen Halpain; Lawrence A Palinkas; Dilip V Jeste
Journal:  Schizophr Bull       Date:  2010-07-05       Impact factor: 9.306

Review 3.  New wine in old bottle: late-life psychosis.

Authors:  Alana Iglewicz; Thomas W Meeks; Dilip V Jeste
Journal:  Psychiatr Clin North Am       Date:  2011-06

4.  Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole.

Authors:  Izchak Kohen; Paula E Lester; Sum Lam
Journal:  Neuropsychiatr Dis Treat       Date:  2010-03-24       Impact factor: 2.570

5.  Serotonergic hyperinnervation and effective serotonin blockade in an FGF receptor developmental model of psychosis.

Authors:  Ilona Klejbor; Aaron Kucinski; Scott R Wersinger; Thomas Corso; Jan H Spodnik; Jerzy Dziewiatkowski; Janusz Moryś; Renae A Hesse; Kenner C Rice; Robert Miletich; Ewa K Stachowiak; Michal K Stachowiak
Journal:  Schizophr Res       Date:  2009-07-01       Impact factor: 4.939

Review 6.  The neurodevelopmental hypothesis of schizophrenia, revisited.

Authors:  S Hossein Fatemi; Timothy D Folsom
Journal:  Schizophr Bull       Date:  2009-02-17       Impact factor: 9.306

7.  Clinical Practice Guideline for Management of Psychoses in Elderly.

Authors:  Shiv Gautam; Akhilesh Jain; Manaswi Gautam; Anita Gautam
Journal:  Indian J Psychiatry       Date:  2018-02       Impact factor: 1.759

8.  The status of serum cortisol before and after treatment of schizophrenia and its correlation to disease severity and improvement: A longitudinal study.

Authors:  Yohannes Markos Woldesenbet; Arefayne Alenko; Iyasu Tadesse Bukata; Lealem Gedefaw; Chaltu Fikru
Journal:  SAGE Open Med       Date:  2021-11-09

Review 9.  Psychotic disorders in late life: a narrative review.

Authors:  Rajesh R Tampi; Juan Young; Rakin Hoq; Kyle Resnick; Deena J Tampi
Journal:  Ther Adv Psychopharmacol       Date:  2019-10-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.